🇺🇸 FDA
Pipeline program

Peak value anti-Xa

2022-2-2016

Unknown other active

Quick answer

Peak value anti-Xa for Venous Thromboembolism is a Unknown program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Venous Thromboembolism
Phase
Unknown
Modality
other
Status
active

Clinical trials